News | January 18, 2021
Zydus eyes $6 bn market with strong COVID-19 portfolio
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
In FY 2020-2021 (upto 12th January 2021) Jan Aushadhi Kendras have completed sales of Rs. 484 crores at 7,064 Pradhan Mantri Bhartiya Jan Aushadhi Kendras
Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
Subscribe To Our Newsletter & Stay Updated
